Orion Oyj (STU:OFK) Future Policy Benefits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:OFK Orion Oyj STU:OFK
97 GF Score
Price €83.00
GF Value €74.28
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Orion Oyj Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.

STU:OFK
97GF Score
Orion Oyj STU:OFK
Future Policy Benefits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orion Oyj (STU:OFK) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued. The current stock price of €83.00 is trading 11.7% above its estimated GF Value™ of €74.28. GuruFocus considers Orion Oyj to be Modestly Overvalued.

Key valuation signals for STU:OFK:

  • Future Policy Benefits:
  • GF Value™: €74.28 vs. price of €83.00 (11.7% above fair value)
  • GF Score™: 97/100 with 4 warning signs

No single metric tells the full story. See the STU:OFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Oyj Business Description

Address Orionintie 1, Espoo, FIN, FI-02200
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary drugs as well as active pharmaceutical ingredients. Its main therapeutic areas include central nervous system disorders, oncology, and respiratory diseases, and it also produces generic medicines and self-care products. The Veterinary division supplies animal health products, while Fermion manufactures active ingredients for Orion and external customers. Customers include physicians, veterinarians, pharmacies, hospitals, and laboratories. Orion operates through two main segments, Pharmaceuticals and Veterinary, and sells primarily in Finland and other European countries, with additional operations in North America and elsewhere. Revenue comes from branded prescription medicines, generics, veterinary products, and contract manufacturing of active ingredients, with a significant share generated in Finland.
97GF Score

Get the complete analysis for STU:OFK

Future Policy Benefits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€83.00
Price
€74.28
GF Value